Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children – A systematic review and a meta-analysis
| Autor: | Alicia M. Fry, William G. Davis, Min Z. Levine, Angela P Campbell, Kathryn E. Lafond, Melissa A Rolfes, Lauren Beacham, Eduardo Azziz-Baumgartner, Sarah Spencer, Mark G. Thompson, Manish M. Patel |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Squalene medicine.medical_specialty Influenza vaccine MF59 Polysorbates law.invention 03 medical and health sciences Influenza A Virus H1N1 Subtype 0302 clinical medicine Randomized controlled trial Immunity law 030225 pediatrics Internal medicine Influenza Human medicine Humans 030212 general & internal medicine Child Randomized Controlled Trials as Topic Hemagglutination assay General Veterinary General Immunology and Microbiology business.industry Influenza A Virus H3N2 Subtype Immunogenicity Public Health Environmental and Occupational Health Infant Confidence interval Infectious Diseases Influenza Vaccines Child Preschool Meta-analysis Molecular Medicine Female business |
| Zdroj: | Vaccine. 38:608-619 |
| ISSN: | 0264-410X |
| Popis: | Identifying optimal priming strategies for children2 years could substantially improve the public health benefits of influenza vaccines. Adjuvanted seasonal influenza vaccines were designed to promote a better immune response among young vaccine-naïve children.We systematically reviewed randomized trials to assess hemagglutination inhibition (HAI) antibody response to MF59-adjuvanted inactivated influenza vaccine (aIIV) versus nonadjuvanted IIV among children. We estimated pooled ratios of post-vaccination HAI geometric mean titer (GMT) for aIIV versus IIV and confidence intervals (CIs) using the pooled variances derived from reported CIs.Mean age was 28 months (range, 6-72 months). Children received vaccines with either 7.5 μg (6-35 months) or 15 μg (≥36 months) hemagglutinin of each strain depending on age. Seven of eight trials administered trivalent vaccines and one used quadrivalent vaccine. Pooled post-vaccination GMT ratios against the three influenza vaccine strains were 2.5-3.5 fold higher after 2-dose-aIIV versus 2-dose-IIV among children 6-72 months, and point estimates were higher among children 6-35 months compared with older children. When comparing 1-dose-aIIV to 2-dose-IIV doses, pooled GMT ratios were not significantly different against A/H1N1 (1.0; 95% CI: 0.5-1.8; p = 0.90) and A/H3N2 viruses (1.0; 95% CI: 0.7-1.5; p = 0.81) and were significantly lower against B viruses (0.6; 95% CI: 0.4-0.8; p 0.001) for both age groups. Notably, GMT ratios for vaccine-mismatched heterologous viruses after 2-dose-aIIV compared with 2-dose-IIV were higher against A/H1N1 (2.0; 95% CI: 1.1-3.4), A/H3N2 (2.9; 95% CI: 1.9-4.2), and B-lineage viruses (2.1; 95% CI: 1.8-2.6).Two doses of adjuvanted IIV consistently induced better humoral immune responses against Type A and B influenza viruses compared with nonadjuvanted IIVs in young children, particularly among those 6-35 months. One adjuvanted IIV dose had a similar response to two nonadjuvanted IIV doses against Type A influenza viruses. Longer-term benefits from imprinting and cell-mediated immunity, including trials of clinical efficacy, are gaps that warrant investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect